Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
New Jersey
-
New Brunswick、New Jersey、美国
- University of Medicine and Dentistry of New Jersey
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、美国、19104
- Abramson Cancer Center of the University of Pennsylvania
-
Pittsburgh、Pennsylvania、美国
- University of Pittsburgh, Hillman Cancer Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 1 Histological evidence of metastatic renal cell carcinoma that has been previously treated with 1-3 prior regimens
- 2 Phase I only, any number of prior regimens with evidence of progressive disease
- 3 Patients must have at least one measurable site of disease according to RECIST criteria that has not been previously irradiated. If the patient has had previous radiation to the marker lesion(s), there must be evidence of progression since the radiation
- 4 Age 18 years
- 5 Eastern Cooperative Oncology Group (ECOG) performance status £
- 6 Adequate bone marrow function as shown by: absolute neutrophil count (ANC) 1.5 x 109/L, Platelets 100 x 109/L, Hb 9 g/dL
- 7 Adequate liver function as shown by:
- 8 Serum bilirubin 1.5 x upper limit of normal
- 9 ALT and aspartate aminotransferase (AST) 2.5x upper limit of normal ( 5x upper limit of normal in patients with liver metastases)
- 10 international normalized ratio (INR) and PTT 1.5. (Anticoagulation is allowed if target INR 1.5 on a stable dose of warfarin or on a stable dose of anticoagulant for 2 weeks at time of randomization.) Adequate renal function: serum creatinine 2.0 x upper limit of normal or Creatinine Clearance 60 .11 Fasting serum cholesterol 300 mg/dL OR 7.75 mmol/L AND fasting triglycerides 2.5 x upper limit of normal . NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.
- 12 Signed informed consent
Exclusion Criteria:
.1. Patients currently receiving anticancer therapy or who have received anticancer therapy within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.). To prevent explosive disease progression associated with angiogenic rebound from impacting the results of this study, patients who have received prior antiangiogenic therapy in the form of a small molecule multikinase inhibitor or bevacizumab must be off prior therapy for 1 week and have antiangiogenic therapy-associated adverse events (AEs) resolve to grade 2 before starting study treatment.
- 2 Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery or patients that may require major surgery during the course of the study
- 3 Prior treatment with any investigational drug within the preceding 4 weeks .4 Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
- 5 Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
- 6 Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
- 7 Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin, Stage I resected melanoma, ductal carcinoma in situ, squamous cell carcinoma of the skin, resected, basal cell carcinoma, indolent prostate cancer
- 8 Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
- 9 Symptomatic congestive heart failure of New York heart Association Class III or IV
- 10 Unstable angina pectoris, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
- 11 Severely impaired lung function with a previously documented spirometry and diffusing capacity of lung for carbon monoxide that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air
- 12 Uncontrolled diabetes as defined by fasting serum glucose 1.5 x ULN
- 13 Active (acute or chronic) or uncontrolled severe infections
- 14 Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
- 15 A known history of HIV seropositivity as reported by the patient
- 16 Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)
- 17 Patients with an active, bleeding diathesis
- 18 Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception. (Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001)
- 19 Patients who have received prior treatment with an mammilian target of rapamycin (mTOR) inhibitor (sirolimus, temsirolimus, everolimus).(Phase I prior mTOR inhibitor allowed)
- 20 Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients
- 21 History of noncompliance to medical regimens
- 22 Patients unwilling to or unable to comply with the protocol .23 A detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening for all patients. HBV DNA and HCV RNA polymerase chain reaction testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Intervention - Dose Level 1
RAD001 given 10mg/daily by mouth and 400mg hydroxychloroquine twice daily by mouth.
Cycle 1 will include 1 week run-in of RAD001.
Following this, both RAD001 and hydroxychloroquine given without interruption.
Cycle 1 duration is 35 days; all subsequent cycles are 28 days.
RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
|
其他名称:
其他名称:
|
实验性的:Intervention - Dose Level 2 Phase 2
RAD001 given 10mg/daily by mouth and 600mg hydroxychloroquine twice daily by mouth.
Cycle 1 will include 1 week run-in of RAD001.
Following this, both RAD001 and hydroxychloroquine given without interruption.
Cycle 1 duration is 35 days; all subsequent cycles are 28 days.
RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
|
其他名称:
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
无进展生存期
大体时间:6个月
|
6个月
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.